201 related articles for article (PubMed ID: 30693788)
1. Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review.
Kini SD; Yiu DW; Weisberg RA; Davila JF; Chelius DC
Ann Otol Rhinol Laryngol; 2019 May; 128(5):467-471. PubMed ID: 30693788
[TBL] [Abstract][Full Text] [Related]
2. [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia].
Xu C; Wang HT
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jun; 51(6):476-9. PubMed ID: 27345893
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
Parambil JG; Woodard TD; Koc ON
Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia: An Evidence-based Review.
Halderman AA; Ryan MW; Marple BF; Sindwani R; Reh DD; Poetker DM
Am J Rhinol Allergy; 2018 Jul; 32(4):258-268. PubMed ID: 29745243
[TBL] [Abstract][Full Text] [Related]
5. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.
Stokes P; Rimmer J
Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422
[TBL] [Abstract][Full Text] [Related]
6. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
[TBL] [Abstract][Full Text] [Related]
7. Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia.
Khoueir N; Borsik M; Camous D; Herman P; Verillaud B
Laryngoscope; 2019 Oct; 129(10):2210-2215. PubMed ID: 31566760
[TBL] [Abstract][Full Text] [Related]
8. Intranasal bevacizumab injections improve quality of life in HHT patients.
Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S
Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573
[TBL] [Abstract][Full Text] [Related]
9. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial.
Riss D; Burian M; Wolf A; Kranebitter V; Kaider A; Arnoldner C
Head Neck; 2015 Jun; 37(6):783-7. PubMed ID: 24595923
[TBL] [Abstract][Full Text] [Related]
10. Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series.
Rosenberg T; Fialla AD; Kjeldsen J; Kjeldsen AD
Rhinology; 2019 Aug; 57(4):242-251. PubMed ID: 30907391
[TBL] [Abstract][Full Text] [Related]
11. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature.
Arizmendez NP; Rudmik L; Poetker DM
Int Forum Allergy Rhinol; 2015 Nov; 5(11):1042-7. PubMed ID: 26202958
[TBL] [Abstract][Full Text] [Related]
12. Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia.
Feller CN; Adams JA; Friedland DR; Poetker DM
Am J Otolaryngol; 2022; 43(3):103409. PubMed ID: 35216850
[TBL] [Abstract][Full Text] [Related]
13. Randomized, controlled, double-blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization.
Khanwalkar AR; Rathor A; Read AK; Paknezhad H; Ma Y; Hwang PH
Int Forum Allergy Rhinol; 2022 Aug; 12(8):1034-1042. PubMed ID: 34989143
[TBL] [Abstract][Full Text] [Related]
14. Long-term experience with intranasal bevacizumab therapy.
Steineger J; Osnes T; Heimdal K; Dheyauldeen S
Laryngoscope; 2018 Oct; 128(10):2237-2244. PubMed ID: 29469958
[TBL] [Abstract][Full Text] [Related]
15. Medical Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Meta-analysis.
Hsu YP; Hsu CW; Bai CH; Cheng SW; Chen C
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):22-35. PubMed ID: 30200816
[TBL] [Abstract][Full Text] [Related]
16. ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
Dupuis-Girod S; Ambrun A; Decullier E; Samson G; Roux A; Fargeton AE; Rioufol C; Schwiertz V; Disant F; Chapuis F; Donazzolo Y; Paintaud G; Edery P; Faure F
MAbs; 2014; 6(3):794-9. PubMed ID: 24481211
[TBL] [Abstract][Full Text] [Related]
17. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
[TBL] [Abstract][Full Text] [Related]
19. Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for Clinicians.
Al-Samkari H
Semin Thromb Hemost; 2022 Jul; 48(5):514-528. PubMed ID: 35226946
[TBL] [Abstract][Full Text] [Related]
20. Hereditary hemorrhagic telangiectasia/avastin.
Davidson TM; Olitsky SE; Wei JL
Laryngoscope; 2010 Feb; 120(2):432-5. PubMed ID: 19998344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]